Science
Nuvectis Pharma Reports Q1 Results, Expects Several Clinical Updates in H2 2024
Nuvectis Chairman & CEO Ron Bentsur: “2024 is shaping up to be a potentially transformational year for Nuvectis with several clinical data updates expected in the second half of the year.”